270 results about "Lipopolysaccharide" patented technology

The invention discloses a fish by-product active peptide, a preparation and application, and belongs to the technical field of biological active peptides. The amino acid sequences of the fish by-product active peptide are shown as SEQ ID NO: 1 to SEQ ID NO: 3. Both the single peptide fragment and the compound peptide fragment of the fish by-product active peptide can obviously inhibit NO secretion of a lipopolysaccharide (LPS)-induced macrophage (RAW264.7) inflammation model, so that the fish by-product active peptide has a relatively good application prospect in preparation of a product with an anti-inflammatory effect; and a foundation is laid for high-added-value utilization of salmon byproducts and promotion of research, development and application of functional active peptides.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention relates to a biomarker for screening intestinal flora transplantation donors and application of the biomarker. The biomarker comprises intestinal flora and metabolites thereof, the intestinal flora comprises phylum firmicalis, bacteroides and the like, and the metabolites comprise short-chain fatty acid, tryptophan, indole, 5-hydroxytryptamine, lipopolysaccharide and the like. According to the method, the intestinal flora of different crowds is deeply analyzed, the relationship between each related index of the intestinal flora and the intestinal flora transplantation effect is studied, sufficient clinical verification is carried out, a biomarker for screening the intestinal flora transplantation donor is excavated, and a standard for judging whether the intestinal flora transplantation donor is qualified or not is established; and a new method and a new idea are provided for efficiently and accurately screening intestinal flora transplantation donors.

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

The invention provides an extraction and detection method of a day lily active matter and application of the day lily active matter in anti-neuritis. Hemerocallis fulva contains various bioactive substances including flavone, polysaccharide and saponin, and the substances have potential application value in the fields of medicines and health care products. The invention provides a method for extracting the active components step by step, and rapid identification and detection are carried out by utilizing technologies such as fluorescence and ultraviolet-visible spectrophotometry. In addition, the invention also develops a detection method for evaluating the anti-neuritis effect of the active substances. Lipopolysaccharide (LPS) is used for stimulation to establish an inflammation model, day lily active substances are added, and the active substances are found to be capable of remarkably inhibiting generation and release of inflammatory factors and promoting growth and differentiation of neurons. Scientific basis is provided for developing new neuritis treatment methods, related drugs and the like.

The invention discloses a crocodile polypeptide with anti-inflammatory and intestinal flora regulating functions and a preparation method thereof, belongs to the technical field of functional polypeptide preparation, and particularly relates to a preparation method of the crocodile polypeptide, an anti-inflammatory effect of the crocodile polypeptide and a regulating effect of the crocodile polypeptide on intestinal flora in ulcerative colitis inflammation. According to the preparation method, the crocodile polypeptide is prepared by combining multiple physical processing with enzymolysis, so that the purity and the biological activity of the crocodile polypeptide are improved. On the basis, a lipopolysaccharide-induced THP-1 in-vitro cell inflammation model and a dextran sodium sulfate-induced mouse in-vivo ulcerative colitis inflammation model are established, and the in-vivo and in-vitro anti-inflammatory effect of the crocodile polypeptide is further researched. The crocodile polypeptide prepared by the invention has a remarkable inhibition effect on THP-1 cell inflammation induced by lipopolysaccharide. Meanwhile, the crocodile polypeptide prepared by the preparation method disclosed by the invention has an adjusting effect on intestinal flora. The food or functional food with the effects of relieving ulcerative colitis and regulating intestinal flora can be prepared.

The invention belongs to the technical field of genetic engineering, and particularly relates to application of miRNA related to cow mastitis. The invention provides an application of miR-320b in preparation of a medicine for treating dairy cow mastitis, the nucleotide sequence of the miR-320b is shown as SEQ ID NO.1, and the miR-320b is used for diagnosing the process of resisting Escherichia coli, E. coli type dairy cow mastitis. The miR-320b expression quantity of the miR-320b in the dairy cow mammary epithelial cells or E. coli type mammary tissue induced by lipopolysaccharide (LPS) is detected, and when the expression quantity of the miR-320b is obviously reduced, the miR-320b is prompted to have an anti-inflammatory function in the dairy cow mastitis.

The application belongs to the technical field of natural medicinal chemistry, and discloses a benzofuran compound in Jinyunming and a preparation method and application thereof. The benzofuran compound is separated from Jinyunming of the plant Dalbergia hupeana Tutch in the family of Leguminosae. The heartwood of Jinyunming is extracted and concentrated to obtain extract, the extract is sequentially separated by multiple silica gel column chromatography, medium-pressure ODS column chromatography and gel column chromatography, and then purified by semi-preparative high-performance liquid chromatography, so that the benzofuran compound can be obtained. The application establishes an inflammation model by inducing RAW 264.7 cells with lipopolysaccharide (LPS), and shows that the compound has good anti-inflammatory activity, the IC50 is 14.33 μM, and the expression of inflammatory factors interleukin-6 (IL-6) and interleukin-1β (IL-1β) can be inhibited.

The invention belongs to the technical field of biological detection, and particularly relates to a preparation method of lipopolysaccharide-beta-1, 3-glucan binding protein and application of the lipopolysaccharide-beta-1, 3-glucan binding protein in preparation of a broad-spectrum colloidal gold detection product for dermatophytes. The prokaryotic expression system induces the procambarus clarkii-sourced lipopolysaccharide-beta-1, 3-glucan binding protein to be efficiently expressed in an inclusion body form, the optimized inclusion body purification-renaturation process is combined to realize batch preparation, and the colloidal gold chromatography technology is integrated, so that the procambarus clarkii-sourced lipopolysaccharide-beta-1, 3-glucan binding protein is obtained. The bottlenecks of the traditional detection method in sensitivity, broad spectrum and field applicability are broken through.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

It is considered that diabetes-associated dementia is mainly caused by insulin resistance and relative insulin deficiency in the brain. Delivery of drugs to the brain is inhibited by the blood-brain barrier, and therefore, there has been so far no drug that provides excellent drug delivery to the brain. Therefore, there has been no wonder drug for diabetes-associated dementia. LPSs have a high molecular weight and therefore do not pass through the blood-brain barrier. It is possible to provide a composition for a drug, food, or the like that has the effect of preventing and treating impairment due to diabetes-associated dementia, by means of a lipopolysaccharide derived from a bacterium belonging to the genus Pantoea. A lipopolysaccharide derived from a bacterium belonging to the family Enterobacteriaceae is confirmed to be safe when used for oral or transdermal administration in the form of food, cosmetics, feed, or the like, and thus can be expected to provide prophylactic and therapeutic effects with a low risk of side effects.

The invention relates to biomedical engineering, and discloses a biochip screening method of a therapeutic agent based on intestinal brain axis regulation and application thereof. The screening method comprises the following steps: performing intestinal wall cell culture or microglial cell culture by adopting a metasurface plasmon resonance biochip of which the surface is subjected to bionic treatment to obtain an intestinal wall cell adherent chip board or a microglial cell adherent chip board; the method comprises the following steps: adding a culture medium containing a chemotherapeutic drug or lipopolysaccharide into a cell-adherent chip board for culture I, then removing the culture medium, adding a therapeutic agent to be detected for culture II to obtain a culture solution, and detecting the cell repair effect of intestinal wall cells or microglial cells in the culture solution, and screening to obtain a therapeutic agent with a repairing effect on intestinal wall cells and / or microglial cells. The screening method can be used for efficiently and accurately screening the therapeutic agent with dual effects of intestinal regulation and neuroprotection from a plurality of therapeutic agents to be detected, and can be used for dynamically monitoring and exploring the interaction condition of the therapeutic agent and cells on line in an unmarked and real-time manner.

The invention belongs to the technical field of natural pharmaceutical chemistry, and discloses a flavonoid compound in lomatogonium radiatum as well as a preparation method and application thereof.The flavonoid compound is separated from lomatogonium radiatum of a gentiaceae lomatogonium plant, the medicinal material of lomatogonium radiatum is extracted and concentrated, and the flavonoid compound is obtained. And sequentially carrying out macroporous adsorption resin separation, gel column chromatography separation, medium-low pressure ODS column chromatography separation and semi-preparative high performance liquid chromatography separation. Pharmacological studies show that the compound provided by the invention can effectively inhibit the levels of COX2, IL-6 and TNF-alpha in mouse macrophages RAW246.7 caused by lipopolysaccharide (LPS), which indicates that the compound has obvious anti-inflammatory activity and can be used for preparing anti-inflammatory drugs.

The present application belongs to the field of microbial culture, and particularly relates to a culture medium for reducing expression of surface polysaccharide of Vibrio parahaemolyticus. The formula of the polysaccharide low-expression culture medium is selected from specific proportion of nutritional components and specific conditions for inhibiting polysaccharide expression, so that the expression amount of surface lipopolysaccharide and capsule polysaccharide of Vibrio parahaemolyticus after the culture medium is increased is lower than the expression amount of polysaccharide of Vibrio parahaemolyticus after normal culture, the expression of surface lipopolysaccharide and capsule polysaccharide can be inhibited to a certain extent, the surface of the bacterial body can better expose outer membrane protein, and the immunodetection of Vibrio parahaemolyticus is facilitated. The present application provides a technical basis for developing a complete immunodetection method of Vibrio parahaemolyticus.

This invention discloses a hydrogel for tumor treatment based on improving the tumor microenvironment to trigger gas therapy combined with chemotherapy, belonging to the field of biomedical technology. The hydrogel drug delivery system utilizes lipopolysaccharide (LPS) to induce local inflammatory stimulation, thereby altering the tumor microenvironment of breast cancer and promoting nitric oxide (NO) production. The NO donor arginine (L-Arg) and the chemotherapy drug doxorubicin (DOX) are transported using sodium alginate (ALG), achieving combined gas therapy and chemotherapy to inhibit breast tumor growth. The drug delivery system of this invention not only enhances the effect of chemotherapy but also simultaneously achieves precise drug delivery and reduces drug dosage. The preparation method of the drug delivery system of this invention is simple, safe, and without toxic side effects, showing promising application prospects in tumor treatment and possessing significant clinical value.

The invention relates to the technical field of biology, in particular to a pine bark polyphenol extract as well as a preparation method and application thereof. According to the present invention, the pine tree bark polyphenol extract is obtained through extraction with an ethanol solution, and the pine tree bark polyphenol extract mainly comprises 2-Hydroxy-4-hydroxybenzoic acid, Pinosylvin, Hispidulin, 3, 5-Dimethoxyphenol, 2, 3, 5, 4 '-Tetrahydroxystilbene, 2-O-beta-D-glucose, Quercetin-3-O-glucose, 6-O-Caffeoyl-D-glucose, Galvantinol, MeIAA and Rhapontigenin, and the pine tree bark polyphenol extract can be used for preparing the pine tree bark polyphenol extract, and can be used for preparing the pine tree bark polyphenol extract, the pine tree bark polyphenol extract, the pine tree bark polyphenol extract, the pine tree bark polyphenol extract, the pine tree bark polyphenol extract, the pine tree bark polyphenol extract and the preparation method thereof, the pine bark polyphenol extract can be used for effectively relieving LPS (lipopolysaccharide)-induced intestinal barrier injury of weaned piglets by regulating intestinal flora (improving Pediococcus abundance and reducing Alloprevotella abundance) and a tryptophan-AhR pathway under the condition that the addition amount of the pine bark polyphenol extract is lower than 0.05 wt%.

The invention relates to a pharmaceutical composition consisting of a liposomal formulation of a phospholipid component and an aqueous phase, wherein the phospholipid component is selected from the group consisting of phosphatidylcholine, and sphingomyelin, and wherein the phospholipid component comprises a saturated or mono-unsaturated (Z / cis) fatty acid having 14 to 20 carbon atoms. The invention further relates to the use of the pharmaceutical composition in treatment of a condition associated with presence of lipopolysaccharide (LPS), particularly endotoxemia.

The invention relates to a triterpenoid saponin compound, a preparation method thereof and application of the triterpenoid saponin compound in preparation of anti-neuroinflammation drugs. The triterpenoid saponin compound has a structure as shown in a formula I. An in-vitro anti-neuroinflammation activity experiment proves that the triterpenoid saponin compound has an obvious inhibition effect on lipopolysaccharide (LPS)-induced BV2 cell inflammation, and can be used as a novel anti-neuroinflammation drug and a neurodegenerative disease treatment drug. Formula I

The invention discloses armillariella mycelium polysaccharide ATMP capable of improving cognitive impairment and a preparation method and application of the armillariella mycelium polysaccharide ATMP. The polysaccharide is composed of two components, and the molecular weights of the two components are 2.30 * 10 < 4 > Da and 4.56 * 10 < 5 > Da respectively; the monosaccharide composition comprises mannose (Man), glucose (Glc) and galactose (Gal), and the molar ratio of the mannose (Man) to the glucose (Glc) to the galactose (Gal) is 1: 16.64: 1.96. Animal experiment results show that the armillariella mycelium polysaccharide ATMP can improve cognitive impairment induced by lipopolysaccharide (LPS) by improving the spatial memory ability of mice, repairing the disorder state and deletion injury of neurons in a hippocampal region and relieving neuroinflammatory response, so that the obvious neuroprotective effect is achieved. As a natural brain-benefiting active component, the armillariella tabescens mycelium polysaccharide ATMP has a wide application prospect in the related fields of brain health.

The disclosure relates to anti-inflammatory, oxygen-scavenging membrane vesicles derived from bacteria with modified or absent lipopolysaccharide. The disclosure further relates to pharmaceutical and nutritional compositions comprising these vesicles, and methods of using the same. Methods include therapeutic treatment of diseases associated with gut oxygenation and inflammation, such as inflammatory bowel disease, as well as non-therapeutic methods for supporting gastrointestinal health, promoting a healthy inflammatory response, and maintaining a balanced gut microbiota.

The invention discloses a hederacoside C deglycosylation derivative and a preparation method and application thereof.The hederacoside C deglycosylation derivative is prepared from hederacoside C through specific glycosidase hydrolysis, different products can be flexibly regulated and enriched on the basis of selectivity of different glycosidase to glucosidic bonds and glycosyl sites, the preparation method is simple, reaction conditions are mild, and the hederacoside C deglycosylation derivative is suitable for industrial production. The method is suitable for large-scale mass production. The hederacoside C deglycosyl derivative does not show obvious cytotoxicity to human immortalized keratinocytes, has the effect of promoting cell proliferation and the activity of promoting cell migration, and can obviously inhibit LPS (lipopolysaccharide)-induced cell apoptosis. Besides, the partial hederacoside C deglycosyl derivatives can reduce inflammatory factor level rise caused by wounds, remarkably promote wound healing and reduce formation of wound scars, and have good application prospects in preparation of drugs or skin care products for promoting wound repair.

The invention provides a 3-hydroxypyrone derivative as well as a preparation method and application thereof, the compound can effectively inhibit release of proinflammatory cytokines in lipopolysaccharide-induced microglial cells, inhibit release of NO by the lipopolysaccharide-induced microglial cells, inhibit apoptosis of polysaccharide-induced microglial cells, and inhibit apoptosis of lipopolysaccharide-induced microglial cells. The compound has excellent anti-neuroinflammation activity and neuroprotective effect, the activity of the compound is superior to that of positive controls such as curcumin and hydrocortisone, and the compound can be used for preventing and / or treating neuroinflammation and neurodegenerative diseases.

The invention provides a medicine for treating sepsis-related acute kidney injury, belongs to the technical field of small molecule medicines, and particularly provides a medicine for treating sepsis-related acute kidney injury, which comprises a NOX4 inhibitor. And the NOX4 inhibitor comprises GLX351322 (GLX351322). According to the application, it is clear that the NOX4 level in serum of an S-AKI patient is remarkably increased and is in positive correlation with kidney injury, it is proved that GLX351322 has remarkable treatment and renal function protection effects on acute kidney injury caused by bacterial infection or acute kidney injury caused by lipopolysaccharide exposure, and a new treatment target and a new drug development direction are provided for sepsis-related acute kidney injury.

The invention provides an application of 10E, 12Z-octadecadienoic acid in inhibition of inflammatory reactions, and the inflammatory reactions comprise macrophage inflammatory reactions induced by lipopolysaccharide. According to the invention, a mouse mononuclear macrophage RAW264.7 cell inflammatory response model is constructed. The method comprises the following steps: firstly, measuring CC50 of 10E, 12Z-octadecadienoic acid by a CCK-8 method; 10E, 12Z-octadecadienoic acid is used for pretreating macrophages for 24 hours before lipopolysaccharide stimulation at the final concentration of 25 mu mol / L to 100 mu mol / L, qPCR (quantitative polymerase chain reaction) and ELISA (enzyme-linked immuno sorbent assay) experiments prove that the 10E, 12Z-octadecadienoic acid plays an anti-inflammatory role by inhibiting mRNA (messenger ribonucleic acid) expression and protein secretion of IL-6, IL-1beta and / or TNF-alpha, and the anti-inflammatory effect is optimal at the final concentration of 100 mu mol / L. The 10E, 12Z-octadecadienoic acid is a single unmodified fatty acid isomer, is clear in structure, good in anti-inflammatory effect repeatability and good in biocompatibility, and can reduce adverse reactions compared with traditional anti-inflammatory drugs; compared with existing fatty acid anti-inflammatory components, the composition is clear in component and simple and convenient to prepare. The application scenarios of the invention cover the development of anti-inflammatory drugs, functional foods and biological agents.

This invention relates to the use of a natural terpene compound in pharmaceuticals, said natural terpene compound having the structure shown in formula (I), and having the function of preparing a compound for the prevention or treatment of hypoxia-inducible factor-1. α Use in medicines for diseases associated with abnormally elevated activity. This invention has discovered that the compound possesses hypoxia-inducible factor-1. α It exhibits inhibitory activity, effectively suppressing macrophage inflammatory responses and hepatocyte damage. It also demonstrates significant protective function against lipopolysaccharide / galactosamine-induced acute liver injury in mice, and can be used as a lead compound for the preparation of new drugs or drugs for the prevention and treatment of acute liver injury.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

This invention discloses a compound soft capsule based on camellia oil and its preparation method, belonging to the field of health food processing technology. Using camellia oil as the core carrier, this invention combines extracts of honeysuckle, green tea, and licorice root, using beeswax as a specific suspending agent, without adding any wetting agents. By optimizing the entire process parameters from ultrasonic extraction of traditional Chinese medicine, content preparation, sol-gel, pelleting, shaping, washing, drying, and packaging, a compound soft capsule with high stability, good flowability, and clear anti-inflammatory effects is prepared. This invention solves the technical problems of easy oxidation and deterioration of camellia oil, insufficient deep processing in the camellia oil industry, and low economic added value. The resulting soft capsules can effectively inhibit pro-inflammatory factors such as TNF-α, IL-2, and IFN-γ, increase the level of the anti-inflammatory factor IL-10, and have a significant protective effect against lipopolysaccharide-induced acute kidney injury. The process of this invention is controllable and suitable for industrial production, which can significantly extend the camellia oil industry chain and enhance the competitiveness of the local woody oilseed industry.

The invention discloses a protein with lipopolysaccharide degrading enzyme activity and a gene and application thereof. The invention belongs to the field of gene engineering, and particularly relates to a protein with lipopolysaccharide degrading enzyme activity and a gene and application thereof. The protein disclosed by the invention is any one of the following proteins: 1) an amino acid sequence is SEQ ID No: 9 or SEQ ID No: 5 in a sequence table; 2) a protein which is obtained by substituting and / or deleting and / or adding one or more amino acid residues to the protein in 1) and has the same function; and 3) a fusion protein obtained by connecting a protein tag to the N terminal or / and C terminal of 1) or 2). The protein ALP3 with lipopolysaccharide degrading enzyme activity developed by the invention lays a foundation for low-cost production of high-yield novel lipopolysaccharide degrading enzyme, and has important application potential in biodegradation of endotoxin in the aquatic product field.

The present application provides a kind of protecting group B meningococcal infection outer membrane vesicle composition, the outer membrane vesicle composition is by lipopolysaccharide modified group B meningococcal outer membrane vesicle and the outer membrane vesicle of group B meningococcal bacterium expressing recombinant protein is composed.The outer membrane vesicle composition provided by the present application has better protective effect on group B meningococcal infection relative to single strain outer membrane vesicle, and is more suitable for use as vaccine.

The invention discloses application of KLF14 agonist perhexiline in preparation of a medicine for treating acute lung injury, and belongs to the technical field of biological medicine. The high expression of the KLF14 in the acute lung injury model lung is systematically clarified. KLF14 is inhibited by adopting adenovirus knock-down, and it is found that KLF14 deletion can aggravate acute lung injury induced by lipopolysaccharide by mediating release of neutrophil NETosis and inflammatory factors. The activation of the perhexiline on the KLF14 can effectively inhibit the release of neutrophil NETosis and inflammatory factors, so that the lung morphological change caused by lipopolysaccharide can be inhibited in vivo, the lung interstitial inflammatory cell infiltration is weakened, and the effect of relieving the acute lung injury is achieved. The invention provides an application of perhexiline as a KLF14 agonist in relieving acute lung injury, and provides a new therapeutic target and therapeutic drug for prevention and treatment of acute lung injury.